Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.

Thrombosis research - 1 Jan 2006

Castelló Remedios, España Francisco, Vázquez Carlos, Fuster Carlos, Almenar Sergio M, Aznar Justo, Estellés Amparo

Abstract excerpt

BACKGROUND: The plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism may have significance for PAI-1 expression. High levels of PAI-1 in breast cancer patients are associated with a poor prognosis. In this study, we analyzed the influence of the PAI-1 4G/5G polymorphism on tissue PAI-1 levels and its association with tumor severity in women with breast cancer. MATERIAL AND METHODS: We studied 104...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunosorbent Assay

Share to Plasminogen Activator Inhibitor 1

Share to Polymorphism, Genetic

Share to Prognosis

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Severity of Illness Index

Source

Identifiers

PMID: 15907980
DOI: 10.1016/j.thromres.2005.03.025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.PMID 15907980Read ↗

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.Semantic proximity Read ↗

Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.Semantic proximity Read ↗

PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.Semantic proximity Read ↗

Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.Semantic proximity Read ↗

Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.Semantic proximity Read ↗

The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.Semantic proximity Read ↗

Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.Semantic proximity Read ↗

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.